Positive Phase 3 Topline Results Announced for NT-501 Implant in MacTel

November 2, 2022

Neurotech Pharmaceuticals, Inc. announces positive Phase 3 topline results for NT-501 implant in macular telangiectaisa type 2 (MacTel).  (Cumberland, RI)

Clinically relevant and statistically significant primary results with the NT-501 implant demonstrated change in the rate of progression of disease in Macular telangiectasia type 2 (MacTel) patients in two pivotal Phase 3 Trials; 56.4% rate of reduction in Protocol A (p<0.0001) and 29.2 % rate of reduction in Protocol B (p=0.021)

View full Press Release here for NT-501 Phase 3 Trials